Roche gets FDA approval for Vabysmo to treat nAMD and DME
Vabysmo inhibits disease pathways that drive neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Feb 22
Vabysmo inhibits disease pathways that drive neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
01 Feb 22
Spikevax is the second Covid-19 vaccine to get full approval in the US, following Pfizer and BioNTech’s Covid-19…
31 Jan 22
The EC approval was based on results from the Phase 3 CROWN trial, in which Lorviqua reduced the…
28 Jan 22
The positive CHMP recommendation was based on evidence supporting Paxlovid, including data from the Phase 2/3 EPIC-HR trial
25 Jan 22
The US agency revised the EUAs for Lilly’s bamlanivimab plus etesevimab regimen, and Regeneron’s REGEN-COV, based on the…
25 Jan 22
Gefapixant is a non-narcotic selective P2X3 receptor antagonist intended for the treatment of refractory (RCC) or unexplained chronic…
24 Jan 22
The US FDA has also expanded the emergency use authorisation of remdesivir to include the treatment of non-hospitalised…
18 Jan 22
The company has submitted the Phase 2 trial data for its mRNA vaccine candidate to India’s Central Drugs…
17 Jan 22
Cibinqo is an oral, once-daily, oral small molecule that selectively inhibits Janus kinase 1 (JAK1), to modulate multiple…
17 Jan 22
Zydelig will be continued as a treatment for CLL and FL in the European Union (EU), the UK,…